MedTrace Logo

Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering From What is Known as Long COVID (LC)

NCT06437223 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2026-03-06

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the safety and efficacy of Xiflam versus Placebo in patients who present with signs and symptoms of Long COVID.

Xiflam (n=10) or placebo (n=5) will be administered orally once a day (QD) for 12 weeks.

Conditions

Interventions

DRUG

Tonabersat

Tonabersat 40mg. Two tablets per day

DRUG

Placebo

Placebo 40mg, Two tablets per day

Sponsors & Collaborators

  • Inflammx Therapeutics Inc

    lead INDUSTRY

Principal Investigators

  • Peter Chang, MD · Massachusetts Eye Research and Surgery Institution (MERSI)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-12
Primary Completion
2025-09-30
Completion
2025-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06437223 on ClinicalTrials.gov